• In April 2026, Amprius Technologies replaced BDO with Deloitte as its independent auditor and outlined a busy May schedule of industry exhibitions, defense-focused presentations, and investor conferences spotlighting its silicon anode battery solutions.
• These auditor changes and highly visible appearances, alongside fresh institutional interest from firms like Jane Street and Palisades Investment Partners, highlight growing scrutiny and engagement around Amprius’ technology, governance, and market positioning in advanced battery applications.
• With Amprius preparing to showcase NDAA-compliant battery solutions for defense and aerospace audiences, we’ll now examine how this shapes its investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.

Amprius Technologies Investment Narrative Recap

To own Amprius, you need to believe its silicon anode batteries can convert niche aviation and drone traction into a broader, scalable business while tightening losses. The key near term catalyst is execution on its 2026 revenue and loss guidance, and the biggest risk remains concentration in early stage aviation and drone demand. The auditor switch to Deloitte and the May conference circuit do not materially change those fundamentals, but they increase external scrutiny of Amprius’ story.

Among the recent announcements, the expanded manufacturing footprint through the Amprius Korea Battery Alliance and Nanotech Energy partnership stands out. These moves are tightly linked to the catalyst of turning NDAA compliant defense and aerospace interest into recurring, higher margin revenue, while also touching the risk side by relying on external partners in multiple regions for capacity and supply chain resilience.

Yet behind the technology buzz and new auditor, investors should be aware that customer concentration in aviation and drones still leaves Amprius exposed if...

Amprius Technologies' narrative projects $306.6 million revenue and $13.4 million earnings by 2028. This requires 89.8% yearly revenue growth and a $52.1 million earnings increase from $-38.7 million today.

Uncover how Amprius Technologies' forecasts yield a $19.25 fair value, a 8% downside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming about US$315.8 million of revenue and US$31.8 million of earnings by 2029, which frames a much more pessimistic view on execution and supply chain risk than the consensus. As this new NDAA focused and auditor related news plays out, you may find that those more cautious expectations either soften or harden, so it is worth comparing these very different scenarios for yourself.

Explore 8 other fair value estimates on Amprius Technologies - why the stock might be worth less than half the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Amprius Technologies research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Amprius Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amprius Technologies' overall financial health at a glance.

No Opportunity In Amprius Technologies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.